Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2021

Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting

Katherine Francis
  • Fonction : Auteur
Val Gebski
  • Fonction : Auteur
Sarah Lord
  • Fonction : Auteur
Michael Friedlander
  • Fonction : Auteur
Chee Khoon Lee
  • Fonction : Auteur
Fichier non déposé

Dates et versions

hal-03236358 , version 1 (26-05-2021)

Identifiants

Citer

Katherine Francis, Val Gebski, Sarah Lord, Michael Friedlander, Eric Pujade-Lauraine, et al.. Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting. European Journal of Cancer, 2021, 148, pp.251-259. ⟨10.1016/j.ejca.2021.02.006⟩. ⟨hal-03236358⟩
19 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More